GeNeuro

News

GeNeuro announces completion of recruitment of its long-COVID Phase 2 trial and confirms top-line results for June 2024

HERV Approach

GeNeuro is pursuing a novel approach for treating autoimmune diseases by seeking to block mechanisms suspected of participating to their onset and development.